The board is thinking long term. Market doesn’t think long term. Can I discuss thoughts around valuation. Geographic expansion of illuccix is a given as is the kidney diagnostic approval. 35-40 per cent revenue growth of illuccix in North America I can only imagine fy25 revenue to be 2b AUD.
what about therapy? Ignoring therapy what do you think valuation is based on the above $30 AUD ?
The board is thinking long term. Market doesn’t think long term....
-
- There are more pages in this discussion • 1,286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.78 |
Change
-0.120(0.52%) |
Mkt cap ! $7.624B | |||
| Open | High | Low | Value | Volume |
| $22.52 | $22.78 | $22.42 | $12.91M | 570.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 31056 | $22.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.80 | 2670 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |